Kanso Diagnostics vs Nucleix
Kanso Diagnostics vs Nucleix, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Kanso Diagnostics is on 53/100 and Nucleix on 56/100.
Where each one leads
Kanso Diagnostics
- headcount growth: +22.1% against +7.1%
Nucleix
- our overall score: 56/100 against 53/100
- domain rating: 38/100 against 1/100
- headcount: 74 against 7
- funding raised: $102M against $1.8M
- LinkedIn following: 7,846 against 778
At a glance
| Measure | Kanso Diagnostics | Nucleix |
|---|---|---|
| What it is | Develops a proprietary, stand-alone platform for rapid, lab-grade molecular diagnostics at the point of need. | Nucleix is a liquid biopsy company developing early cancer detection solutions using methylation analysis. |
| Category | Healthcare, Diagnostics, Genetics, Pathology | Healthcare, Lung, Bladder, Cancer |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Software |
| Founded | 2021 | 2008 |
| Headquarters | Or Yehuda, Israel | Rehovot, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | Kanso Diagnostics | Nucleix |
|---|---|---|
| Employees | 7 | 74 |
| Headcount growthLast 12 months | +22.1% | +7.1% |
| Total funding | $1.8M | $102M |
| Latest round | Seed | Funding Round |
| LinkedIn followers | 778 | 7,846 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Kanso Diagnostics | Nucleix |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 53/100 | 56/100 |
| Traction | 40/100 | 59/100 |
| Team | 70/100 | 70/100 |
| Community | 8/100 | Not published |
| Search visibility | 39/100 | 36/100 |
| Quality | 58/100 | 55/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (28/100) | F (30/100) |
| Domain ratingLink authority, 0-100 | 1/100 | 38/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Kanso Diagnostics | Nucleix |
|---|---|---|
| Hosting | Netlify | Not detected |
| CDN | Netlify | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Analytics 4 |
What users say
| Measure | Kanso Diagnostics | Nucleix |
|---|---|---|
| Reddit sentimentThreads we track | Not published | 6 positive, 0 negative across 6 threads |
“Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes.”r/LungCancerSupport
Kanso Diagnostics vs Nucleix: common questions
Which is better, Kanso Diagnostics or Nucleix?
On our 0-100 score Nucleix rates higher (56/100 against 53/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do Kanso Diagnostics and Nucleix compare on the numbers?
Kanso Diagnostics leads on headcount growth (+22.1% against +7.1%). Nucleix leads on our overall score (56/100 against 53/100), domain rating (38/100 against 1/100), headcount (74 against 7), funding raised ($102M against $1.8M), LinkedIn following (7,846 against 778).
What do real users say about Kanso Diagnostics and Nucleix?
Nucleix: 6 positive and 0 negative mentions across 6 Reddit threads we track, mostly in r/LungCancerSupport.
Read the full Kanso Diagnostics review and pricing or the Nucleix review and pricing. You can also browse other Kanso Diagnostics alternatives we track.